Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Journal of Clinical Endocrinology and Metabolism

• Publication date

  1996-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1210/JCEM.81.8.8768828PMID 8768828
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 23 Pituitary Adenylate Cyclase Activating Peptideによるモルモット気管平滑筋反応の検討

  1995cited by this paper
• Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue.

  1995cited by this paper
• Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age.

  1994cited by this paper
• Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects.

  1994cited by this paper
• GROWTH HORMONE RESPONSE TO WAR WOUNDS: 9

  1994cited by this paper
• The effects of human growth hormone (GH) administration in GH-deficient adults: a 20-day metabolic ward study.

  1994cited by this paper
• On a peptidomimetic growth hormone-releasing peptide.

  1994cited by this paper
• Serum insulin‐like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin

  1994cited by this paper
• Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus.

  1993cited by this paper
• Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men.

  1993cited by this paper
• Reduced bone mineral content in adult patients with growth hormone deficiency.

  1993cited by this paper
• Insulin-like growth factors and their binding proteins in plasma and milk after growth hormone-stimulated galactopoiesis in normally lactating women.

  1993cited by this paper
• A nonpeptidyl growth hormone secretagogue.

  1993cited by this paper
• Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6.

  1993cited by this paper
• Stimulation of growth hormone release from rat primary pituitary cells by L-692,429, a novel non-peptidyl GH secretagogue.

  1993cited by this paper
• Pituitary adenylate cyclase activating polypeptide, growth hormone (GH)-releasing peptide and GH-releasing hormone stimulate GH release through distinct pituitary receptors.

  1992cited by this paper
• The growth hormone deficiency syndrome in adults

  1992cited by this paper
• Computers in endocrinology : recent advances

  1992cited by this paper
• Circadian modulation of glucose and insulin responses to meals: relationship to cortisol rhythm.

  1992cited by this paper
• A quantitative estimation of growth hormone secretion in normal man: reproducibility and relation to sleep and time of day.

  1992cited by this paper
• Intranasal administration of His-D-Trp-Ala-Trp-D-Phe-LysNH2 (growth hormone releasing peptide) increased plasma growth hormone and insulin-like growth factor-I levels in normal men.

  1991cited by this paper
• Effects of human growth hormone on body composition in elderly men.

  1991cited by this paper
• Neuroendocrine rhythms and sleep in aging men.

  1991cited by this paper
• Desensitization studies using perifused rat pituitary cells show that growth hormone-releasing hormone and His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 stimulate growth hormone release through distinct receptor sites.

  1991cited by this paper
• On the actions of the growth hormone-releasing hexapeptide, GHRP.

  1991cited by this paper
• Effects of human growth hormone in men over 60 years old.

  1990cited by this paper
• Effects of short term administration of recombinant human growth hormone to elderly people.

  1990cited by this paper
• Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone.

  1990cited by this paper
• The free hormone hypothesis: a physiologically based mathematical model.

  1989cited by this paper
• Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates.

  1989cited by this paper
• The synergistic effects of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 on growth hormone (GH)-releasing factor-stimulated GH release and intracellular adenosine 3',5'-monophosphate accumulation in rat primary pituitary cell culture.

  1989cited by this paper
• Half-time of endogenous growth hormone (GH) disappearance in normal man after stimulation of GH secretion by GH-releasing hormone and suppression with somatostatin.

  1989cited by this paper
• Effect of a new synthetic hexapeptide to selectively stimulate growth hormone release in healthy human subjects.

  1989cited by this paper
• Estimating false-positive and false-negative errors in analyses of hormonal pulsatility

  1988cited by this paper
• Estimating false-positive and false-negative errors in analyses of hormonal pulsatility.

  1988cited by this paper
• On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone.

  1984cited by this paper
• The interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion.

  1984cited by this paper
• Impaired growth hormone secretion in the adult population: relation to age and adiposity.

  1981cited by this paper
• Quantitative Methods for the Analysis of Circadian and Episodic Hormone Fluctuations

  1981cited by this paper
• Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma.

  1981cited by this paper
• Robust Locally Weighted Regression and Smoothing Scatterplots

  1979cited by this paper
• A manual of standardized terminology, technique and scoring system for sleep stages of human subjects

  1968cited by this paper
• Effect of estrogen administration on extravascular cortisol.

  1966cited by this paper
• AN ADRENAL-SECRETED "ANDROGEN": DEHYDROISOANDROSTERONE SULFATE. ITS METABOLISM AND A TENTATIVE GENERALIZATION ON THE METABOLISM OF OTHER STEROID CONJUGATES IN MAN.

  1965cited by this paper
• [The anterior pituitary of the fetus].

  1962cited by this paper

• Knowing the minimal detectable dose can facilitate the interpretation of a hair test result: II. Case example with ibutamoren (MK-677), a growth hormone secretagogue.

  2025cites this paper
• Beyond Hunger: The Structure, Signaling, and Systemic Roles of Ghrelin

  2025cites this paper
• Изучение метаболизма секретагога гормона роста ибутаморена (MK-677) в моче человека методом ультравысокоэффективной жидкостной хроматографии-масс-спектрометрии высокого разрешения

  2024cites this paper
• Microglia in the TBI brain: The good, the bad, and the dysregulated.

  2016cites this paper
• Adipokines and Cardiovascular Risk in Cushing’s Syndrome

  2011cites this paper
• Use of Growth Hormone Secretagogues to Prevent or Treat the Effects of Aging: Not Yet Ready for Prime Time

  2008cites this paper
• Role of ghrelin in growth hormone-deficient patients

  2006cites this paper
• Growth Hormone-Releasing Hormone: Clinical Perspectives Revisited

  2005cites this paper
• L'hormone de croissance : un dopant ?

  2005cites this paper
• Glucagon inhibits ghrelin secretion in humans.

  2005cites this paper
• Endocrine and metabolic effects of growth hormone (GH) compared with GH-releasing peptide, thyrotropin-releasing hormone, and insulin infusion in a rabbit model of prolonged critical illness.

  2004cites this paper
• Ghrelin does not mediate the somatotroph and corticotroph responses to the stimulatory effect of glucagon or insulin‐induced hypoglycaemia in humans

  2004cites this paper
• Hexarelin decreases slow-wave sleep and stimulates the secretion of GH, ACTH, cortisol and prolactin during sleep in healthy volunteers.

  2004cites this paper
• Ghrelin--a hormone with multiple functions.

  2004cites this paper
• Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin.

  2004cites this paper
• Natural and Synthetic Growth Hormone Secretagogues

  2003cites this paper
• Pattern-dependent suppression of growth hormone (GH) pulsatility by ghrelin and GH-releasing peptide-6 in moderately GH-deficient rats.

  2003cites this paper
• [Growth hormone and doping].

  2003cites this paper
• Diagnosis and management of growth hormone deficiency in childhood and adolescence--part 2: growth hormone treatment in growth hormone deficient children.

  2002cites this paper
• Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans.

  2002cites this paper
• GH and cortisol rebound rise during and following a somatostatin infusion: studies in dogs with the use of a GH-releasing peptide.

  2002cites this paper
• Growth hormone secretagogues: discovery of small orally active molecules by peptidomimetic strategies.

  2002cites this paper
• Ghrelin: The Link Connecting Growth with Metabolism and Energy Homeostasis

  2002cites this paper
• Prolactin-releasing activity of GHRP-5 (Momany peptide) on lactotrophs in vivo and in vitro.

  2002cites this paper
• Orally active growth hormone secretagogues.

  2002cites this paper
• Sleep and Hormonal Rhythms in Humans

  2001cites this paper
• Recombinant human IGF-I does not modify the ACTH and cortisol responses to hCRH and hexarelin, a peptidyl GH secretagogue, in humans

  2001cites this paper
• Skeletal Growth Acceleration with Growth Hormone Secretagogues in Transgenic Growth Retarded Rats: Pattern‐Dependent Effects and Mechanisms of Desensitization

  2001cites this paper
• Pharmacokinetic and Pharmacodynamic Modeling of NN703, a Growth Hormone Secretagogue, after a Single po Dose to Human Volunteers

  2001cites this paper
• Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.

  2001cites this paper
• Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone–insulin‐like growth factor I axis in growth hormone–deficient children

  2001cites this paper
• The pharmacokinetics, pharmacodynamics, safety and tolerability following 7 days daily oral treatment with NN703 in healthy male subjects.

  2001cites this paper
• Decline of life’s energy theory of ageing 2. Restoration of anabolic and regulatory processes

  2000cites this paper
• Differences of Hexarelin-induced Prolactin and Cortisol Responses Between Prepubertal and Early Pubertal Short Children and Lack of Correlation with Gonadotropin-Releasing Hormone-induced Gonadotropin Response

  2000cites this paper
• Clinical Use of Growth Hormone Secretagogues

  2000cites this paper
• Glucocorticoid regulation of growth hormone (GH) secretagogue-induced growth responses and GH secretagogue receptor expression in the rat.

  2000cites this paper
• Interactions Between Growth Hormone Secretion and Sleep

  2000cites this paper
• Interrelationships between growth hormone and sleep.

  2000cites this paper
• The pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN703, a novel orally active growth hormone secretagogue in healthy male volunteers.

  2000cites this paper
• Effect of growth hormone secretagogue LY444711 on IGF‐1, growth hormone, and cortisol levels in beagle dogs after one and seven daily oral doses

  2000cites this paper
• The Design of Peptidomimetic Growth Hormone Secretagogues

  2000cites this paper
• Endocrine activities of alexamorelin (Ala-His-d-2-methyl-Trp-Ala-Trp-d-Phe-Lys-NH2), a synthetic GH secretagogue, in humans.

  2000cites this paper
• Interrelationships between growthhormone and sleep

  2000cites this paper
• Growth hormone and the aging male

  1999cites this paper
• Chapter 9 – Mechanisms of Actions of Growth Hormone-Releasing Peptides and their Analogues In Vivo

  1999cites this paper
• Growth hormone secretagogues: recent advances and applications.

  1999cites this paper
• Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a).

  1999cites this paper
• Chapter 21 – Therapeutic Potential of GH Secretagogues in Adults

  1999cites this paper
• Chapter 12 – Hormonal Activities of Growth Hormone Secretagogues (GHS) across Human Lifespan

  1999cites this paper
• Chapter 15 – GHRP-s in Human Obesity

  1999cites this paper
• Neuroendocrine control of growth hormone secretion.

  1999cites this paper
• Pharmacological characterisation of a new oral GH secretagogue, NN703.

  1999cites this paper
• Oral Administration of the Growth Hormone Secretagogue MK‐677 Increases Markers of Bone Turnover in Healthy and Functionally Impaired Elderly Adults

  1999cites this paper
• Discrepancy between serum leptin values and total body fat in response to the oral growth hormone secretagogue MK‐677

  1999cites this paper
• Six-week treatment with hexarelin in young dogs: evaluation of the GH responsiveness to acute hexarelin or GHRH administration, and of the orexigenic effect of hexarelin.

  1999cites this paper
• Effects of Growth Hormone‐Releasing Peptide‐6 on the Nocturnal Secretion of GH, ACTH and Cortisol and on the Sleep EEG in Man: Role of Routes of Administration

  1999cites this paper
• Growth hormone secretagogues and sleep.

  1999cites this paper
• Effects of the combined administration of hexarelin, a synthetic peptidyl GH secretagogue, and hCRH on ACTH, cortisol and GH secretion in patients with Cushing’s disease

  1999cites this paper
• Growth Hormone Secretagogues: Physiological Role and Clinical Utility.

  1999cites this paper
• Ipamorelin, the first selective growth hormone secretagogue.

  1998cites this paper
• MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.

  1998cites this paper
• Interrelations between sleep and the somatotropic axis.

  1998cites this paper
• Growth hormone secretagogues: mechanism of action and use in aging.

  1998cites this paper
• Treatment with the Oral Growth Hormone Secretagogue MK‐677 Increases Markers of Bone Formation and Bone Resorption in Obese Young Males

  1998cites this paper
• Effects of Dexamethasone and Alprazolam, a Benzodiazepine, on the Stimulatory Effect of Hexarelin, a Synthetic GHRP, on ACTH, Cortisol and GH Secretion in Humans

  1998cites this paper
• Orally active growth hormone secretagogues: state of the art and clinical perspectives.

  1998cites this paper
• Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.

  1998cites this paper
• Diagnostic and therapeutic uses of growth hormone-releasing substances in adult and elderly subjects.

  1998cites this paper
• Effects of repeated doses and continuous infusions of the growth hormone-releasing peptide hexarelin in conscious male rats.

  1998cites this paper
• [New growth hormone secretagogues: from physiology to the first therapeutic applications].

  1998cites this paper
• A five day treatment with daily subcutaneous injections of growth hormone-releasing peptide-2 causes response attenuation and does not stimulate insulin-like growth factor-I secretion in healthy young men.

  1998cites this paper
• Growth hormone-releasing peptides and their analogs.

  1998cites this paper
• Growth hormone secretagogues as corticotrophin-releasing factors.

  1998cites this paper
• Effects of Hormones on Sleep

  1998cites this paper
• 10 Diagnostic and therapeutic uses of growth hormone-releasing substances in adult and elderly subjects

  1998cites this paper
• Les nouveaux sécrétagogues de l'hormone de croissance De la physiologie aux premières applications thérapeutiques

  1998cites this paper
• Growth Hormone‐Releasing Peptides

  1998cites this paper
• The Growth Hormone Secretory Pattern and Statural Growth

  1998cites this paper
• Growth Hormone, Growth Hormone Releasing Peptides

  1998cites this paper
• Age‐related growth hormone‐releasing activity of growth hormone secretagogues in humans

  1997cites this paper
• The prevention or treatment of age‐related osteoporosis in the elderly by systemic recombinant growth factor therapy (rhIGF‐I or rhTGFβ): a perspective

  1997cites this paper
• Compensatory functions and therapies in the elderly--everything is not lost.

  1997cites this paper
• Hypothalamic targets for growth hormone secretagogues

  1997cites this paper
• Neuropeptides and human sleep.

  1997cites this paper
• Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man.

  1997cites this paper
• Growth hormone-releasing peptides.

  1997cites this paper
• Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH.

  1997cites this paper
• Hexarelin, a synthetic growth-hormone releasing peptide, shows no interaction with corticotropin-releasing hormone and vasopressin on adrenocorticotropin and cortisol secretion in humans.

  1997cites this paper
• The GH, prolactin, ACTH and cortisol responses to Hexarelin, a synthetic hexapeptide, undergo different age-related variations.

  1997cites this paper
• Stimulation du sommeil avec un secretagogue d'hormone de croissance

  1997cites this paper
• Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man

  1997cites this paper
• Endocrinology. Youthful hormones.

  1996cites this paper
• Oral growth hormone secretagogues--better than Alice in Wonderland's growth elixir?

  1996cites this paper